Objective To assess the ability of 5 cerebrospinal fluid (CSF) biomarkers to differentiate
between common dementia and parkinsonian disorders. Design A cross-sectional, clinic-based …

Objective: To investigate whether certain CSF biomarkers at baseline can predict future
progression of motor symptoms and cognitive decline in patients with Parkinson disease (PD). …

The first lab-on-chip system for picoliter droplet generation and PCR amplification with real-time
fluorescence detection has performed PCR in isolated droplets at volumes 10 6 smaller …

Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …

Objective The purpose of this study was to investigate whether cerebrospinal fluid (CSF)
levels of tau, phosphorylated tau, β‐amyloid 42 , α‐synuclein, neurofilament light, and YKL‐40 …

Objective: To determine if blood neurofilament light chain (NfL) protein can discriminate
between Parkinson disease (PD) and atypical parkinsonian disorders (APD) with equally high …

There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients
with cognitive impairment, especially when coexisting with Alzheimer’s disease (AD) …

Neuroinflammation may be involved in the pathophysiology of Parkinson’s disease (PD) and
specifically in non-motor symptoms such as depression, fatigue and cognitive impairment. …

α-Synuclein aggregates constitute the pathology of Lewy body (LB) disease. Little is known
about the effects of LB pathology in preclinical (presymptomatic) individuals, either as …

Inflammation has been implicated in the pathogenesis of Parkinson’s disease (PD). We
here investigate levels of inflammatory biomarkers in cerebrospinal fluid (CSF) in PD and …